Literature DB >> 29789676

The angiotensin-I-converting enzyme insertion/deletion in polymorphic element codes for an AluYa5 RNA that downregulates gene expression.

Fernando F P Mafra1, Pedro P Gattai1, Michel M Macedo1, Marcelo A Mori1, Ronaldo C Araujo2.   

Abstract

Angiotensin-I-converting enzyme (ACE) is involved in the synthesis and degradation of important bioactive peptides. The ACE gene has a 287-bp insertion/deletion polymorphism that controls ACE expression through a mechanism that remains elusive. In this study, we found that the 287-bp polymorphic element of the ACE gene, a member of the AluYa5 sub-family of Alu elements, codes for an RNA molecule that controls the levels of ACE mRNA. Transient transfection of a plasmid containing a CMV promoter upstream of the ACE polymorphic element resulted in significant expression of an AluYa5 RNA and reduced ACE mRNA expression as well as ACE enzymatic activity in AD 293 cells. The AluYa5 element also independently reduced the expression of other genes, regardless of whether these genes harbored Alu elements within their genomic context. Interestingly, the CMV promoter was not required for the expression of the AluYa5 element in AD 293 cells. The 287-bp sequence was sufficient to produce AluYa5 RNA and led to a significant reduction in ACE gene expression. Moreover, the removal of an 11-bp fragment of the 3' end of the ACE polymorphic sequence, which is specific to this particular AluYa5 element, did not prevent this element from being expressed but did affect its ability to target ACE expression. Thus, the expression of the AluYa5 polymorphic element within the ACE gene could explain why patients carrying the ACE insertion polymorphism have reduced risk of developing several chronic diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29789676     DOI: 10.1038/s41397-018-0020-x

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  5 in total

Review 1.  Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.

Authors:  Soudeh Ghafouri-Fard; Rezvan Noroozi; Mir Davood Omrani; Wojciech Branicki; Ewelina Pośpiech; Arezou Sayad; Krzysztof Pyrc; Paweł P Łabaj; Reza Vafaee; Mohammad Taheri; Marek Sanak
Journal:  Vascul Pharmacol       Date:  2020-05-11       Impact factor: 5.773

Review 2.  Alu retrotransposons and COVID-19 susceptibility and morbidity.

Authors:  Manci Li; Luca Schifanella; Peter A Larsen
Journal:  Hum Genomics       Date:  2021-01-04       Impact factor: 4.639

Review 3.  Malaria, COVID-19 and angiotensin-converting enzyme 2: what does the available population data say?

Authors:  A De; M Dash; A Tiwari; A Sinha
Journal:  Open Biol       Date:  2021-10-13       Impact factor: 6.411

4.  Angiotensin-converting-enzyme insertion/deletion polymorphism, ACE activity, and COVID-19: A rather controversial hypothesis. A case-control study.

Authors:  Anna Papadopoulou; Paraskevi C Fragkou; Eirini Maratou; Dimitra Dimopoulou; Antonis Kominakis; Ioanna Kokkinopoulou; Christos Kroupis; Athina Nikolaidou; Georgios Antonakos; Vasiliki Papaevangelou; Apostolos Armaganidis; Argirios Tsantes; Eftychia Polyzogopoulou; Sotirios Tsiodras; Anastasia Antoniadou; Paraskevi Moutsatsou
Journal:  J Med Virol       Date:  2021-11-05       Impact factor: 20.693

Review 5.  The association of ACE1, ACE2, TMPRSS2, IFITM3 and VDR polymorphisms with COVID-19 severity: A systematic review and meta-analysis.

Authors:  Zorana Dobrijevic; Dragana Robajac; Nikola Gligorijevic; Miloš Šunderic; Ana Penezic; Goran Miljuš; Olgica Nedic
Journal:  EXCLI J       Date:  2022-06-20       Impact factor: 4.022

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.